Two-step screening method to identify alpha-synuclein aggregation inhibitors for Parkinson's disease

Parkinson's disease is a neurodegenerative disease characterized by the formation of neuronal inclusions of alpha-synuclein in patient brains. As the disease progresses, toxic alpha-synuclein aggregates transmit throughout the nervous system. No effective disease-modifying therapy has been established, and preventing alpha-synuclein aggregation is thought to be one of the most promising approaches to ameliorate the disease. In this study, we performed a two-step screening using the thioflavin T assay and a cell-based assay to identify alpha-synuclein aggregation inhibitors. The first screening, thioflavin T assay, allowed the identification of 30 molecules, among a total of 1262 FDA-approved small compounds, which showed inhibitory effects on alpha-synuclein fibrilization. In the second screening, a cell-based aggregation assay, seven out of these 30 candidates were found to prevent alpha-synuclein aggregation without causing substantial toxicity. Of the seven final candidates, tannic acid was the most promising compound. The robustness of our screening method was validated by a primary neuronal cell model and a Caenorhabditis elegans model, which demonstrated the effect of tannic acid against alpha-synuclein aggregation. In conclusion, our two-step screening system is a powerful method for the identification of alpha-synuclein aggregation inhibitors, and tannic acid is a promising candidate as a disease-modifying drug for Parkinson's disease.